Sign in
CompletedNo phase

Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate

Key facts

Who runs it
Inger Lise Gade
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
101 people enrolled
Started
17 Apr 2020
Ended
31 Dec 2023
Type of study
Observational, 6 groups
Treatments tested
  • Aspergillus specific proteins in exhaled breath condensate (EBC)
  • Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)
Record updated
13 February 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Suspected/confirmed PA patients:; Hospitalized or ambulatory patients with a suspected PA at Aalborg University Hospital; Are conscious and able to understand the given study information; Possess legal capacity; Age above 18 years; Informed, signed consent is obtained; Clinically stable, which is defined as patients with stable blood pressure and not in need for other treatments; No need for organ support, which comprises need for vasopressors or inotropes, mechanical ventilation, extra corporal circulation or renal replacement therapy
  • Controls; Patients as the PA patients, but where the diagnosis of PA is rejected will be included as controls
  • Suspected/confirmed pneumocystis pneumonia patients:; Hospitalized or ambulatory patients with a suspected pneumocystis pneumonia at Aalborg University Hospital - chest x-ray must support the tentative diagnosis of pneumocystis pneumonia; Are conscious and able to understand the given study information; Possess legal capacity; Age above 18 years; Informed, signed consent is obtained; Clinically stable, which is defined as patients with stable blood pressure and not in need for other treatments; No need for organ support, which comprises need for vasopressors or inotropes, mechanical ventilation, extra corporal circulation or renal replacement therapy
  • Controls; Patients as the pneumocystis pneumonia patients, but where the diagnosis is rejected
  • Healthy controls for the confirmed PA patients and confirmed pneumocystis pneumonia patients In addition, 19 healthy controls (i.e. patients/subjects who undergo diagnostic work-up for benign or indolent hematological diseases without suspected PA or pneumocystis pneumonia) will be recruited, as described below; Healthy controls and patients who are going through diagnostic work-up for indolent hematological cancer types or benign hematological diseases, at the Department of Hematology, Aalborg University Hospital; Same gender and age (within a 10-year range) as an included patient with proven/probable/possible PA (15 subjects); Same gender and age (within a 10-year range) as an included patient with verified pneumocystis pneumonia (4 subjects); Are conscious and able to understand the given study information; Possess legal capacity; Age above 18 years; Informed, signed consent is obtained

Who cannot take part

  • PA patients, pneumocystis pneumonia patients and controls:; No upper age limit will be applied

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

In this study, a new, non-invasive method for diagnosis of pulmonary aspergillosis (PA) will be tested in a clinical pilot project.

The 6 groups in the trial

  • PA proven/probable/possible

    15 patients with proven, probable or possible PA

    Treatment: Aspergillus specific proteins in exhaled breath condensate (EBC)

  • PA suspected, not confirmed

    15 patients as the PA patients, but where the diagnosis of PA is rejected.

    Treatment: Aspergillus specific proteins in exhaled breath condensate (EBC)

  • Healthy controls (PA)

    15 subjects of same gender and age as an included patient with proven/probable/possible PA as healthy controls.

    Treatment: Aspergillus specific proteins in exhaled breath condensate (EBC)

  • Pneumocystis pneumonia positive

    Four patients with confirmed pneumocystis pneumonia

    Treatment: Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)

  • Pneumocystis pneumonia negative

    If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control. Four such patients will be included as healthy controls.

    Treatment: Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)

  • Healthy controls (pneumocystis pneumonia)

    Four subjects of same gender and age as an included patient with verified pneumocystis pneumonia as healthy controls.

    Treatment: Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 February 2024